The FDA hold isn't relevant anymore. The trial continued. If it failed the IDMC would have recommend it stop due to futility. If there was a flaw the FDA would have stopped the trial.
In reality the blinded blended data shows survival longer than standard of care. From interim PIII data released in 2018, which was published after the clinical hold ended, 90% of patients got DCVax. In terms of safety we know from earlier trials that DCVax has far fewer reactions that CAR-T. Would UCLA be giving something dangerous to many patients in their own trials? No. Furthermore why would UCLA be treating DCVax as standard of care in their own combination trials if it's some grapefruit juice?
Endpoints were changed by regulators. These are online so you can read that overall survival now will be the goal not progression free survival. Obviously anyone that pays attention knows the difference between overall vs progression free yet you're exploiting investor ignorance. That's the entire purpose of short trolls on this message board.
News 
Market Data 
Discover 
AI
